Growth Hormone Peptides — The Somatotropic Axis Research Toolkit

The Somatotropic Axis: A Multi-Level System

Growth hormone biology isn't one pathway — it's a cascade with multiple control points from the hypothalamus to target tissues. The OSYRIS Growth Hormone category provides research tools at every level:

``` HYPOTHALAMUS │ releases GHRH │ ← Sermorelin, CJC-1295 (GHRH analogs) act HERE │ ← Somatostatin inhibits HERE ▼ PITUITARY (somatotroph cells) │ releases GH in pulses │ ← Ipamorelin (GHRP) amplifies HERE │ ← CJC/Ipamorelin Blend targets BOTH levels ▼ LIVER │ produces IGF-1 in response to GH │ ← IGF1-LR3 acts as the downstream effector ▼ TARGET TISSUES (muscle, bone, fat, organs) │ ← AOD-9604 isolates the fat-specific fragment │ ← Tesamorelin has clinical body composition data ```

Every Node Explained

Level 1: GHRH Analogs (Hypothalamic Stimulation)

Sermorelin — The first 29 amino acids of GHRH. The minimum active fragment. Former FDA approval (Geref) for GH deficiency assessment. Short-acting, produces brief GH pulses mimicking natural GHRH kinetics.

Tesamorelin — Full 44-amino-acid GHRH with a hexenoic acid modification that blocks DPP-IV degradation. Longer-acting than Sermorelin. Current FDA approval (Egrifta) for lipodystrophy. Clinical data on visceral fat reduction and hepatic steatosis.

CJC-1295 (no DAC) — Modified GHRH with improved stability. The "no DAC" version (without Drug Affinity Complex) produces shorter-duration pulses suitable for pulsatile GH research. Available in the CJC/Ipamorelin Blend.

Level 2: GHRPs (Pituitary Amplification)

Ipamorelin — The selective GHRP. Activates GHS-R1a (ghrelin receptor) on pituitary somatotrophs to amplify GH release. No cortisol, prolactin, or aldosterone side effects — unprecedented selectivity in the GHRP class. Available individually and in the CJC/Ipamorelin Blend.

Level 3: Downstream Effectors

IGF1-LR3 — The modified IGF-1 analog with reduced IGFBP binding. Acts at the effector level — the downstream target of GH signaling. Used extensively in cell culture as a growth factor. Allows researchers to study IGF-1 receptor biology independently from upstream GH signaling.

Level 4: Selective Fragments

AOD-9604 — The C-terminal fragment of GH (amino acids 177-191) that retains fat-metabolizing activity without IGF-1 stimulation, growth effects, or glucose/insulin changes. Classified under Metabolic but cross-listed here due to its GH origin.

The Synergy Principle

GHRH and GHRP work through complementary receptor systems on the same cell type:

• GHRH (via GHRH receptor): Stimulates GH gene transcription and primes vesicles for release
• GHRP/Ipamorelin (via GHS-R1a): Amplifies the release signal, increasing the amount of GH released per pulse

In animal models, the combination consistently produces GH output 2-3x greater than either compound alone. This is not additive — it's synergistic. The two receptor systems converge on intracellular signaling cascades (cAMP + calcium) that amplify each other.

The CJC/Ipamorelin Blend provides this combination in a single vial. The no-DAC formulation of CJC-1295 ensures short-duration GH pulses that mimic physiological secretion.

Pulsatile vs Sustained: Why Pattern Matters

Natural GH secretion is pulsatile — bursts every 3-4 hours with the largest pulse during deep sleep. Research has shown that the biological effects of GH depend on the pattern:

• Pulsatile GH preferentially stimulates linear growth, muscle protein synthesis, and lipolysis
• Sustained GH preferentially stimulates liver IGF-1 production, which has both growth-promoting and potentially problematic effects at high sustained levels

Secretagogues (Ipamorelin, Sermorelin, CJC-1295 no DAC) produce pulsatile release. Exogenous GH injection produces sustained elevation. This is a fundamental distinction for research design.

Choosing by Research Level